Abbott News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Abbott India Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Abbott from all sources in a single place.

Abbott India Ltd.

31 Dec 2025, 12:28PM

29025.00

1.20%

Company Update

Abbott India Ltd - 500488 - Intimation Under Regulation 30 Of The Securities And Exchange Board …

BSE India

Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

pdf

Abbott India Ltd.

24 Dec 2025

29025.00

1.20%

Company Update

Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Appointment of Mr. Vivek Mohan (DIN : 00075006) as Additional (Non-Executive) Director with effect from January 1, 2026.

pdf

Abbott India Ltd.

19 Dec 2025

29025.00

1.20%

SAST

Abbott India Ltd - 500488 - Closure of Trading Window

BSE India

Closure of Trading Window for the Unaudited Financial Results for the quarter ending on December 31, 2025.

pdf

Abbott India Ltd.

25 Nov 2025

29025.00

1.20%

Company Update

Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Change in Senior Management Personnel.

pdf

Abbott India Ltd.

24 Nov 2025

29025.00

1.20%

Company Update

Abbott India Ltd - 500488 - Approval Of Central Government For Appointment Of Managing Director

BSE India

Approval of Central Government for appointment of Managing Director

pdf

Abbott India Ltd.

09 Nov 2025

29025.00

1.20%

Operational leverage at play

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q2FY26 revenue grew at a modest pace of 7.6% YoY. We believe moderation in growth was mainly due to discontinuation of insulin pens for Human Mixtard, Levemir and Xultophy by Novo Nordisk in India as it prioritises capacity for GLP-1 brands Ozempic and Wegovy.

Abbott India Ltd. is trading below its 50 day SMA of 29119.6

Abbott India Ltd.

08 Nov 2025

29025.00

1.20%

Abbott India

Buy: Abbott India Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Decent print driven by growth in some power brands- Revenues grew ~8% YoY to 1757 crore. As per IQVIA, some of the power brands such as Thyronorm (Hormonal), Udiliv (GI), Cremaffin Plus (GI) and Duphalac (GI) witnessed decent growth along with some marketed brands of Novo Nordisk and Abbott Healthcare such as Rybelsus (Semaglutide) and Ryzodeg (Insulin). While Mixtard (Insulin) and Novomix (Anti-Diabetic) registered de-growth during the quarter. EBITDA grew ~14% YoY to 502...